Abuse Deterrent Formulations of Prescription Opioids--Reply

Affiliations

Comment

Theodore J Cicero et al. JAMA Psychiatry. 2015 Aug.

. 2015 Aug;72(8):850-1.

doi: 10.1001/jamapsychiatry.2015.0674.

¹ Department of Psychiatry, Washington University in St Louis, St Louis, Missouri.

No abstract available

Comment on

Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ, Ellis MS. Cicero TJ, et al. JAMA Psychiatry. 2015 May;72(5):424-30. doi: 10.1001/jamapsychiatry.2014.3043. JAMA Psychiatry. 2015. PMID: 25760692
Abuse-Deterrent Formulations of Prescription Opioids.
Ruan X, Chiravuri S, Kaye AD. Ruan X, et al. JAMA Psychiatry. 2015 Aug;72(8):849-50. doi: 10.1001/jamapsychiatry.2015.0721. JAMA Psychiatry. 2015. PMID: 26153731 No abstract available.
Abuse-Deterrent Formulations of Prescription Opioids.
Dart RC, Severtson SG, Green JL. Dart RC, et al. JAMA Psychiatry. 2015 Aug;72(8):849. doi: 10.1001/jamapsychiatry.2015.0723. JAMA Psychiatry. 2015. PMID: 26153845 No abstract available.